NovoCure's market cap is currently ―. The company's EPS TTM is $-1.945; its P/E ratio is -6.54; NovoCure is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-0.42. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 127.32M	$ 126.05M	$ 122.18M	$ 128.43M	$ 131.00M
Gross Profit	$ 95.23M	$ 126.05M	$ 92.57M	$ 99.54M	$ 101.25M
EBIT	$ -58.24M	$ -62.66M	$ -51.08M	$ -42.98M	$ -24.61M
EBITDA	$ -62.13M	$ -65.01M	$ -52.41M	$ -43.56M	$ -21.95M
Net Income Common Stockholders	$ -49.48M	$ -57.42M	$ -53.06M	$ -37.30M	$ -26.58M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 921.25M	$ 941.33M	$ 958.71M	$ 969.93M	$ 970.32M
Total Assets	$ 1.15B	$ 1.16B	$ 1.17B	$ 1.15B	$ 1.17B
Total Debt	$ 590.04M	$ 587.48M	$ 586.30M	$ 584.27M	$ 579.50M
Net Debt	$ -331.21M	$ -353.85M	$ -372.41M	$ -385.66M	$ -390.82M
Total Liabilities	$ 752.65M	$ 743.33M	$ 742.19M	$ 1.19B	$ 728.81M
Stockholders Equity	$ 393.70M	$ 415.68M	$ 432.15M	$ 441.17M	$ 445.40M
Cash Flow	-
Free Cash Flow	$ -26.57M	$ -29.67M	$ -22.82M	$ -10.14M	$ 16.72M
Operating Cash Flow	$ -19.31M	$ -22.74M	$ -16.73M	$ -3.71M	$ 22.42M
Investing Cash Flow	$ 17.26M	$ -13.90M	$ 82.29M	$ -128.06M	$ -150.24M
Financing Cash Flow	$ 1.17M	$ 7.50M	$ 5.20M	$ 3.41M	$ 4.20M

Currency in USD

NovoCure Earnings and Revenue History

Income Statement >

NovoCure Debt to Assets

Balance Sheet >

NovoCure Cash Flow

Cash Flow >

NovoCure Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing